VJHemOnc is committed to improving our service to you

iwCLL 2019 | Novel combination therapies in CLL

VJHemOnc is committed to improving our service to you

Matthew Davids

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, speaking at the 18th International Workshop on Chronic Lymphocytic (iwCLL) Biennial Meeting, held in Edinburgh, UK. Davids speaks on achieving measurable residual disease (MRD( negativity through novel combination therapies, touching on current treatment options for Richter’s syndrome.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter